Johnson & Johnson (JNJ.US) today announced results for the third quarter of 2023. The company delivered strong results and significant growth progress in the third quarter, "... providing a solid foundation for future sustainable growth," - Joaquin Duato, chairman of the board and CEO of JnJ, said.
Key details of the report:
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app- Third-quarter 2023 sales growth of 6.8% to $21.4 billion (estimated $21.03 billion), with operating growth of 6.4% and adjusted operating growth of 4.9%. Operating growth excluding COVID-19 vaccine of 9.0%.
- Earnings per share (EPS) of $1.69 increased 4.3%, and adjusted EPS of $2.66 (estimated $2.52) increased 19.3%.
- The company is raising its full-year forecasts for 2023 for sales and adjusted earnings per share (EPS).
Segment results:
Source: JNJ
Earnings forecasts have been raised:
Source: JNJ
More details on the results can be found here.
The company's shares are gaining nearly 1.3% before the opening of the session.
